Xalatan (Latanoprost): A Comprehensive Report

Xalatan, the brand name for latanoprost, is a prostaglandin F2α analogue developed by Pfizer and approved for the treatment of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Since its introduction in the late 1990s, Xalatan has become one of the most widely prescribed first-line therapies for glaucoma worldwide due to its efficacy, convenient once-daily dosing, and favorable systemic safety profile.



Mechanism of Action



Latanoprost is a prodrug that is hydrolyzed by esterases in the cornea to its active free acid form. It selectively binds to FP prostanoid receptors in the ciliary muscle of the eye. This binding increases uveoscleral outflow of aqueous humor, thereby reducing IOP. Unlike earlier glaucoma therapies that primarily decrease aqueous production, latanoprost enhances natural drainage pathways, making it particularly effective in lowering IOP by 25–35% from baseline.



Pharmacokinetics



After topical instillation, latanoprost is rapidly absorbed. Peak IOP reduction occurs approximately 8–12 hours after administration, and the effect can persist for over 24 hours, supporting once-daily dosing. Systemic absorption is minimal and does not produce clinically significant cardiovascular or pulmonary effects, unlike beta-blockers. The drug is metabolized primarily in the liver via fatty acid oxidation, and its metabolites are excreted renally.



Clinical Efficacy



Multiple large-scale randomized controlled trials have demonstrated the superior IOP-lowering efficacy of latanoprost compared to timolol, the historical gold standard. In the pivotal Phase III studies, latanoprost reduced diurnal IOP by 22–34%, while timolol (0.5% twice daily) achieved 18–25% reduction. Latanoprost also provides more consistent IOP control over 24 hours, particularly during the nocturnal period when IOP often peaks.



A meta-analysis of 27 trials concluded that latanoprost reduces mean diurnal IOP by approximately 7–8 mmHg from a baseline of 25 mmHg, with an additional 1–2 mmHg reduction when combined with other agents such as timolol or carbonic anhydrase inhibitors. Fixed-dose combinations like latanoprost-timolol are available for patients requiring even greater lowering.



Indications and Usage



Xalatan is indicated for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension. It is also used off-label for certain types of secondary glaucomas, though its efficacy varies. The recommended dosage is one drop in the affected eye(s) once daily in the evening, as nighttime administration may optimize outflow enhancement.



Safety and Tolerability



The most notable side effect is conjunctival hyperemia (redness), which occurs in up to 30% of patients but is usually mild and self-limiting. Other common ocular adverse effects include eyelash changes (darkening, thickening, and lengthening), iris pigmentation (particularly in patients with mixed-colored irides), periorbital skin darkening, and a risk of macular edema in pseudophakic patients. Systemic side effects are rare; however, there have been reports of respiratory reactions in asthmatic patients.



Long-term use can lead to gradual iris color change, especially in green-blue or hazel eyes, due to increased melanin production. This effect is cosmetic and not associated with pathological changes, but it is permanent and should be discussed with patients.



Contraindications and Precautions



Xalatan is contraindicated in patients with known hypersensitivity to latanoprost or any component of the formulation. Caution is advised in patients with Cialis Super Active 20mg (francescobarletta.it) intraocular inflammation (e.g., iritis, uveitis) and in those with a history of macular edema, as prostaglandin analogues may exacerbate these conditions. The preservative benzalkonium chloride in Xalatan eye drops can cause punctate keratopathy and contact lens discoloration; soft contact lenses should be removed before instillation and replaced after 15 minutes.



Drug Interactions



Formal drug interaction studies are limited, but concurrent use of other prostaglandin analogues should be avoided as they may result in additive side effects without greater efficacy. No significant interactions with systemic medications have been reported.



Comparison with Other Prostaglandin Analogues



Latanoprost is the prototype prostaglandin analogue. Newer agents such as bimatoprost, travoprost, and tafluprost have similar mechanisms but differ in potency, side effects, and preservative formulations. Bimatoprost may produce greater IOP reduction in some patients but is associated with higher rates of hyperemia and periorbital changes. Latanoprost remains widely preferred due to its balance of efficacy, tolerability, and cost.



Clinical Considerations in Practice



Xalatan is often selected as first-line therapy due to its robust IOP lowering and systemic safety. It is particularly valuable in patients who cannot tolerate beta-blockers because of asthma or bradycardia. The once-daily regimen improves adherence compared to multiple daily dosing regimens. However, the common ocular side effects require patient counseling. For patients who develop significant hyperemia or eyelash changes, switching to another prostaglandin or adding a twice-daily beta-blocker may be considered.



Conclusion



Xalatan (latanoprost) remains a cornerstone of glaucoma management more than two decades after its approval. Its proven efficacy in lowering IOP, favorable safety profile, and convenient dosing have established it as a first-line therapeutic option. Ongoing research continues to explore its long-term neuroprotective potential and its role in combination therapies. For the vast majority of patients with open-angle glaucoma or ocular hypertension, Xalatan offers reliable and sustained intraocular pressure control with minimal systemic risk.